Form 4: Establishment Labs Director Ann Custin Acquires Shares in Lieu of Cash Retainer

Director Ann Custin acquired 380 common shares of Establishment Labs Holdings Inc. in lieu of a quarterly cash retainer payment on March 31, 2024.

Summary

• On March 31, 2024, Ann Custin, a director of Establishment Labs Holdings Inc., acquired 380 common shares.
• These shares were received in lieu of a quarterly cash retainer payment, as per the Issuer's Outside Director Compensation Policy.
• The shares were issued under the Issuer's 2018 Equity Incentive Plan.
• The price was determined based on the closing price of the Issuer's common shares on the last trading day of the quarter, at $50.9.
• Following the transaction, Ms. Custin directly owns 12,560 common shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director accepting shares in lieu of cash suggests confidence in the company's stock, but it's a routine transaction.

Positives

• The director's decision to take shares instead of cash may signal confidence in the company's future performance.

Industry Context

Insider transactions are closely watched as they can provide insights into management's perspective on the company's valuation and future prospects. A director choosing to receive shares instead of cash compensation could be interpreted positively.

Comparison to Industry Standards

• Comparing Establishment Labs' director compensation policy with those of similar medical device companies can provide context on whether this arrangement is standard practice.
• Companies like Align Technology, Intuitive Surgical, and Stryker are benchmarks in the medical device industry, and their director compensation structures are publicly available for comparison.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.
• The impact on employees, customers, suppliers, and creditors is negligible.

Key Dates